More on RIGL
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $48.88 |
|
|||
| Open | $48.97 | ||||
| 52 Wk High | $4.38 | ||||
| 52 Wk Low | $1.88 | ||||
| Day High | $49.94 | ||||
| Day Low | $48.56 | ||||
| P/E | N/A | ||||
| EPS | $-1.12 | ||||
| Volume | 20,039 | ||||
- Rigel to present pralsetinib cancer data at ESMO Congress 2026
- Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026
- Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Rigel Pharmaceuticals (RIGL) PT Raised to $49 at Piper Sandler
- Rigel Pharmaceuticals (RIGL) PT Raised to $85 at H.C. Wainwright
- Form SCHEDULE 13G/A RIGEL PHARMACEUTICALS Filed by: ARMISTICE CAPITAL, LLC
- Form SCHEDULE 13G/A RIGEL PHARMACEUTICALS Filed by: Soleus Capital Master Fund, L.P.
- Rigel launches breast cancer drug Veppanu at $29,400 per month
- Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
- Form S-8 RIGEL PHARMACEUTICALS
Entities mentioned with RIGL
- FDA | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- Jefferies & Co | View Related Stories »
- Definitive Agreement | View Related Stories »
- Pre Market Movers | View Related Stories »
- JPMorgan | View Related Stories »
- BMO Capital | View Related Stories »
- Show More...
